Proteomic profiling of kidney samples in patients with pure membranous and proliferative lupus nephritis

被引:3
|
作者
Chen, Yun-Ying [1 ,2 ,3 ]
Ding, Ying [4 ]
Li, Lin-Lin [1 ,2 ,3 ]
Han, Sha-Sha [5 ]
Huang, Min [6 ]
Wong, Catherine C. L. [6 ]
Yu, Feng [1 ,2 ,3 ,4 ]
Zhao, Ming-hui [1 ,2 ,3 ,7 ]
机构
[1] Peking Univ First Hosp, Dept Med, Renal Div, 8 Xishiku St, Beijing 100034, Peoples R China
[2] Peking Univ, Inst Nephrol, Key Lab Renal Dis, Minist Hlth China, 8 Xishiku St, Beijing 100034, Peoples R China
[3] Minist Educ China, Key Lab CKD Prevent & Treatment, 8 Xishiku St, Beijing 100034, Peoples R China
[4] Peking Univ Int Hosp, Dept Nephrol, Beijing, Peoples R China
[5] Beijing Hosp, Natl Ctr Gerontol, Dept Nephrol, Beijing, Peoples R China
[6] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimer Drugs, Beijing, Peoples R China
[7] Peking Univ, Peking Tsinghua Ctr Life Sci, PR China Renal Div, Dept Med,Peking Univ First Hosp,Inst Nephrol, Beijing, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Membranous lupus nephritis; proliferative lupus nephritis; proteomics; pathways; biomarkers; CELL-ADHESION MOLECULE-1; HISTONE DEACETYLASE INHIBITORS; MASS-SPECTROMETRY; PODOCYTE INJURY; PATHOGENESIS; ERYTHEMATOSUS; CLASSIFICATION; INTERFERON; EXPRESSION; PROTEIN;
D O I
10.1177/09612033221094711
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal injury in lupus nephritis (LN) does not manifest as one uniform entity. The clinical presentation, management, and prognosis of membranous LN (MLN) differ from that of the proliferative LN (PLN). Differentiating the molecular mechanisms involved in MLN and PLN and discovering the reliable biomarkers for early diagnosis and target therapy are important. We compared the kidney protein expression patterns of 11 pure MLN and 12 pure PLN patients on formalin-fixed paraffin-embedded (FFPE) kidney tissues using label-free liquid chromatography-mass spectrometry (LC-MS) for quantitative proteomics analysis. FunRich software was used to identify proteins in differentially expressed pathways. Quantitative comparisons of differentially expressed proteins in each patient were further analyzed based on protein intensity levels determined by LC-MS. The protein-protein interaction (PPI) network of the differentially expressed genes (DEGs) was established through Search Tool for the Retrieval of Interacting Genes database (STRING) website, visualized by Cytoscape. A total of 5112 proteins were identified. In total, 12 significantly upregulated (fold change >= 2, p < 0.05) proteins were identified in the MLN group and 220 proteins (fold change >= 2, p < 0.05) were upregulated in the PLN group. Further analysis showed that the most significant upregulated pathway involved in MLN was histone deacetylase (HDAC) class I pathway, and the three most significant upregulated pathways in PLN were interferon signaling, interferon gamma signaling, and the immune system. Next, we selected sirtuin-2 (SIRT2) in MLN, and vascular cell adhesion protein 1 (VCAM1) and Bcl-xl in PLN for further mass spectrometry (MS) intensity and PPI analysis. SIRT2 expression was significantly increased in the MLN group compared with the PLN group, and VCAM1, Bcl-xl expression was significantly increased in the PLN group compared with the MLN group, based on MS intensity. These results may help to improve our understanding of the underlying molecular mechanisms of MLN and PLN and provide potential targets for the diagnosis and treatment of different subclasses of LN.
引用
收藏
页码:837 / 847
页数:11
相关论文
共 50 条
  • [21] Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature
    Silva-Fernandez, Lucia
    Oton, Teresa
    Askanase, Anca
    Carreira, Patricia
    Javier Lopez-Longo, Francisco
    Olive, Alejandro
    Rua-Figueroa, Inigo
    Narvaez, Javier
    Ruiz-Lucea, Esther
    Andres, Mariano
    Calvo, Enrique
    Toyos, Francisco
    Jose Alegre-Sancho, Juan
    Tomero, Eva
    Montilla, Carlos
    Zea, Antonio
    Uriarte, Esther
    Calvo-Alen, Jaime
    Marras, Carlos
    Martinez-Taboada, Victor M.
    Angeles Belmonte-Lopez, Maria
    Rosas, Jose
    Raya, Enrique
    Bonilla, Gema
    Freire, Mercedes
    Maria Pego-Reigosa, Jose
    Millan, Isabel
    Hughes-Morley, Adwoa
    Andreu, Jose Luis
    REUMATOLOGIA CLINICA, 2019, 15 (01): : 34 - 42
  • [22] Multitarget therapy for lupus nephritis with diffuse proliferative and membranous lesions
    Nature Clinical Practice Rheumatology, 2008, 4 (10): : 507 - 507
  • [23] Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
    Sakai, Ryota
    Shibata, Akiko
    Chino, Kentaro
    Kikuchi, Jun
    Kondo, Tsuneo
    Okuyama, Ayumi
    Takei, Hirofumi
    Amano, Koichi
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [24] Differing environmental risk factors for membranous versus proliferative lupus nephritis
    Dooley, M. A.
    Parks, C. G.
    Cooper, G. S.
    ARTHRITIS RESEARCH & THERAPY, 2012, 14
  • [25] Presentation and outcome of paediatric membranous non-proliferative lupus nephritis
    Boris Hugle
    Earl D. Silverman
    Pascal N. Tyrrell
    Elizabeth A. Harvey
    Diane Hébert
    Susanne M. Benseler
    Pediatric Nephrology, 2015, 30 : 113 - 121
  • [26] Podocyte Injury in Membranous and Proliferative Lupus Nephritis: Distinct Underlying Mechanisms?
    Rezende, Gabriela M.
    Viana, Vilma S. T.
    Malheiros, Denise M.
    Leon, Elaine P.
    Borba, Eduardo F.
    Silva, Neila A. S.
    Noronha, Irene L.
    Silva, Cleonice
    Bonfa, Eloisa
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1055 - S1056
  • [27] Treatment of Proliferative and Membranous Lupus Nephritis: Review of Key Clinical Trials
    Alshayeb, Hala
    Wall, Barry M.
    Gosmanova, Elvira O.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 343 (01): : 86 - 90
  • [28] MIXED MEMBRANOUS AND PROLIFERATIVE LUPUS NEPHRITIS PREDICTS POOR RENAL PROGNOSIS
    Hidekazu, Ikeuchi
    Keiju, Hiromura
    Kadiombo, Tshilela A.
    Ken, Kayakabe
    Noriyuki, Sakurai
    Toru, Sakairi
    Yoriaki, Kaneko
    Akito, Maeshima
    Yoshihisa, Nojima
    NEPHROLOGY, 2014, 19 : 51 - 51
  • [29] Use of Urinary Metabolites to Distinguish Proliferative From Membranous Lupus Nephritis
    Nelson, Shannen L.
    Mina, Rina
    Romick-Rosendale, Lindsey
    Brunner, Hermine
    Bennett, Michael
    Pendl, Joshua D.
    Petri, Michelle
    Kiani, Adnan
    Devarajan, Prasad
    Kennedy, Michael
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S794 - S795
  • [30] Differing environmental risk factors for membranous versus proliferative lupus nephritis
    MA Dooley
    CG Parks
    GS Cooper
    Arthritis Research & Therapy, 14 (Suppl 3):